The Health Technology Assessment Approach of the Economic Value of Diagnostic Tests: A Literature Review

David Bardey (), Philippe de Donder () and Vera Zaporozhets ()
Additional contact information
David Bardey: TSE-R - Toulouse School of Economics - UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse - EHESS - École des hautes études en sciences sociales - CNRS - Centre National de la Recherche Scientifique - INRAE - Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement
Philippe de Donder: TSE-R - Toulouse School of Economics - UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse - EHESS - École des hautes études en sciences sociales - CNRS - Centre National de la Recherche Scientifique - INRAE - Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, CNRS - Centre National de la Recherche Scientifique, UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse
Vera Zaporozhets: TSE-R - Toulouse School of Economics - UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse - EHESS - École des hautes études en sciences sociales - CNRS - Centre National de la Recherche Scientifique - INRAE - Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, INRAE - Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse

Post-Print from HAL

Abstract: We review the medico-economic literature assessing the economic value of diagnostic and prognostic tests, with a focus on innovative and, more specifically, companion tests. Our analysis begins with a summary of systematic reviews that provide a descriptive synthesis of existing findings rather than conducting quantitative meta-analyses. These reviews reveal no consistent evidence that such tests outperform traditional approaches, such as pharmaceutical interventions. However, the cost-effectiveness of these tests, often measured in cost per QALY (Quality-Adjusted Life Year) gained, exhibits considerable heterogeneity. Notably, some genetic testing procedures may demonstrate superior performance compared to non-genetic alternatives. We then examine the economic implications of imperfect test features, exploring strategies to optimize their accuracy levels and integrating these considerations into the assessment of their economic value. Lastly, we review recent methodological and empirical studies employing these approaches, highlighting advancements in evaluating the economic impact of diagnostic and prognostic tests.

Keywords: Genetic tests; Innovative tests; Companion tests; Health Technology Assessment (HTA); Personalized medicine; Receiver-operator (ROC) curve; Incremental cost-effectiveness ration (ICER) (search for similar items in EconPapers)
Date: 2025-03-23
Note: View the original document on HAL open archive server: https://hal.science/hal-05024927v1
References: Add references at CitEc
Citations:

Published in Discover Health Systems, 2025, Vol. 4 (N° 26), ⟨10.1007/s44250-025-00196-9⟩

Downloads: (external link)
https://hal.science/hal-05024927v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-05024927

DOI: 10.1007/s44250-025-00196-9

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().